Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

LATEST NEWS

March 10, 2020

Sirnaomics to Showcase Data for Lead Product STP705 in Human Squamous Carcinoma Tumor Model at 2020 American Academy of Dermatology Annual Meeting Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE

March 4, 2020

Sirnaomics to Present at 5th Annual Oligonucleotide & Precision Therapeutics Congress Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE

February 10, 2020

Sirnaomics’ siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today... READ MORE

January 24, 2020

Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV Sirnaomics Inc. (“Sirnaomics”), a leading biopharmaceutical company in discovery and development of novel RNAi therapeutics,... READ MORE

January 13, 2020

Sirnaomics and Junshi Biosciences Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Tuoyi and RNAi in China and US Gaithersburg, MD, USA, and Shanghai, China, January 13, 2020 — Sirnaomics Inc. (“Sirnaomics”), a leading... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...